Abstract
The (sub)type composition of seasonal influenza waves varies in space and time. (Sub)types tend to have different impacts on population groups, therefore understanding the drivers of their co-circulation and anticipating their composition is important for epidemic preparedness and response. FluNet provides data on influenza specimens by (sub)type for more than one hundred fifty countries. However, due to surveillance variations across countries, global analyses usually focus on (sub)type compositions, a kind of data which is difficult to treat with advanced statistical methods. We used Compositional Data Analysis to circumvent the problem and study trajectories of annual (sub)type compositions of countries. First, we examined global trends from 2000 to 2022. We identified a few seasons which stood out for the strong within-country (sub)type dominance due to either a new virus/clade taking over (2003/2004 season, A/H1N1pdm pandemic) or (sub)types’ spatial segregation (COVID-19 pandemic). Second, we showed that the composition trajectories of countries between 2010 and 2019 clustered in two macroregions characterized by (sub)type alternation vs. persistent mixing. Finally, we defined five algorithms for forecasting the next-year composition and we found that taking into account the global history of (sub)type composition in a Bayesian Hierarchical Vector AutoRegressive model improved predictions compared with naive methods. The joint analysis of spatiotemporal dynamics of influenza (sub)types worldwide revealed a hidden structure in (sub)type circulation that can be used to improve predictions of the (sub)type composition of next year’s epidemic according to place.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by: the EU H2020 grant MOOD (H2020-874850) to V.C.; the ANR project DATAREDUX(ANR-19-CE46-0008-03) to V.C.; the Municipality of Paris through the programme Emergence(s) to C.P. and F.B.; Cariparo Foundation through the program Starting Package to C.P.; Department of Molecular Medicine through the program SID from BIRD funding to C.P.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data are available in the FluNet database of W.H.O.: https://www.who.int/tools/flunet
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code and data for reproducible analyses are available at https://github.com/FrancescoBonacina/coupled-dynamics-flu-subtypes/.
https://github.com/FrancescoBonacina/coupled-dynamics-flu-subtypes/
